FIRST-LINE IBRANCEĀ® (PALBOCICLIB) COMBINATION THERAPY IN HR+, HER2- METASTATIC BREAST CANCER
The Pharma Data
MARCH 25, 2021
months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53 lead researcher and Professor in Breast Cancer Excellence in the Perelman School of Medicine at the University of Pennsylvania. months with IBRANCE plus letrozole versus 11.9 to 0.82; P=0.0002). with letrozole.
Let's personalize your content